Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...